CTMX Logo

CytomX Therapeutics, Inc. (CTMX) 

NASDAQ
Market Cap
$78.12M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
513 of 776
Rank in Industry
276 of 433

Largest Insider Buys in Sector

CTMX Stock Price History Chart

CTMX Stock Performance

About CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and …

Insider Activity of CytomX Therapeutics, Inc.

Over the last 12 months, insiders at CytomX Therapeutics, Inc. have bought $0 and sold $173,007 worth of CytomX Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at CytomX Therapeutics, Inc. have bought $7,750 and sold $459,277 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 5,000 shares for transaction amount of $7,750 was made by Jones Elaine V (director) on 2023‑03‑29.

List of Insider Buy and Sell Transactions, CytomX Therapeutics, Inc.

2024-08-20SaleCEO
13,898
0.0176%
$1.23$17,082-5.65%
2024-08-20SaleSVP, Chief Scientific Officer
4,181
0.0053%
$1.23$5,139-5.65%
2024-08-20SaleGeneral Counsel
4,181
0.0053%
$1.23$5,139-5.65%
2024-08-20SaleChief Business Officer
4,181
0.0053%
$1.23$5,139-5.65%
2024-08-20SaleChief Financial Officer
1,984
0.0025%
$1.23$2,439-5.65%
2024-03-19SaleCEO
20,223
0.0286%
$2.09$42,175-34.86%
2024-03-19SaleSVP, Chief Scientific Officer
12,795
0.0181%
$2.09$26,684-34.86%
2024-03-19SaleGeneral Counsel
5,268
0.0074%
$2.09$10,986-34.86%
2024-03-19SaleChief Business Officer
6,562
0.0093%
$2.09$13,685-34.86%
2024-03-19SaleSVP, Finance and Accounting
2,971
0.0042%
$2.09$6,196-34.86%
2023-12-20SaleCEO
13,551
0.0208%
$1.38$18,710+15.58%
2023-12-20SaleSVP, Chief Scientific Officer
4,077
0.0063%
$1.38$5,628+15.58%
2023-12-20SaleGeneral Counsel
4,077
0.0063%
$1.38$5,629+15.58%
2023-12-20SaleChief Business Officer
4,077
0.0063%
$1.38$5,628+15.58%
2023-12-20SaleSVP, Finance and Accounting
1,990
0.0031%
$1.38$2,747+15.58%
2023-09-22SaleCEO
14,601
0.0222%
$1.30$18,987+14.06%
2023-09-22SaleSVP, Chief Scientific Officer
4,119
0.0063%
$1.30$5,356+14.06%
2023-09-22SaleGeneral Counsel
5,486
0.0083%
$1.30$7,135+14.06%
2023-09-22SaleChief Business Officer
4,119
0.0063%
$1.30$5,356+14.06%
2023-03-29Purchasedirector
5,000
0.0076%
$1.55$7,750+0.33%

Insider Historical Profitability

<0.0001%
ROWLAND LLOYD AGeneral Counsel
130797
0.1674%
$1.0016<0.0001%
Flynn James E10 percent owner
671024
0.859%
$1.0010<0.0001%
GLUCK FREDERICK Wdirector
271643
0.3477%
$1.0018<0.0001%
Kavanaugh William MichaelCSO, Head Res.&Non-Clin. Dev.
13917
0.0178%
$1.0011<0.0001%
Jones Elaine Vdirector
5142
0.0066%
$1.0010+0.33%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Bvf Inc Il$14.38M8.476.6M0%+$00.11
Tang Capital Management, LLC$14.06M8.286.45M-1.53%-$218,000.000.05
The Vanguard Group$10.59M6.234.86M-0.93%-$99,340.43<0.0001
OrbiMed$7.73M4.553.54MNew+$7.73M0.06
Acadian Asset Management$5.86M3.452.69M+1.69%+$97,265.270.02
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.